Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017

E Chiong; DG Murphy; H Akaza; NC Buchan; BH Chung; R Kanesvaran; M Khochikar; J Letran; B Lojanapiwat; CF Ng; T Ong; YS Pu; M Saad; K Schubach; L Türkeri; R Umbas; V Le Chuyen; S Williams; DW Ye; ID Davis

Journal article

Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017

E Chiong, DG Murphy, H Akaza, NC Buchan, BH Chung, R Kanesvaran, M Khochikar, J Letran, B Lojanapiwat, CF Ng, T Ong, YS Pu, M Saad, K Schubach, L Türkeri, R Umbas, V Le Chuyen, S Williams, DW Ye, ID Davis

BJU International | WILEY | Published : 2019

DOI: 10.1111/bju.14489

Download PDF

Abstract

Objective: The Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2018) brought together 20 experts from 15 APAC countries to discuss the real-world application of consensus statements from the second APCCC held in St Gallen in 2017 (APCCC 2017). Findings: Differences in genetics, environment, lifestyle, diet and culture are all likely to influence the management of advanced prostate cancer in the APAC region when compared with the rest of the world. When considering the strong APCCC 2017 recommendation for the use of upfront docetaxel in metastatic castration-naïve prostate cancer, the panel noted possible increased toxicity in Asian men receiving docetaxel, which would ..

View full abstract

University of Melbourne Researchers

Declan Murphy Author

Scott Williams Author

Grants

Awarded by Ipsen Biopharmaceuticals

Funding Acknowledgements

The authors gratefully acknowledge the support from Silke Gillessen and Aurelius Omlin for the concept of the APAC APCCC 2018 meeting. Our sincere thanks go to the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group for hosting and coordinating the meeting, with particular thanks to Margaret McJannett and Michelle Bowers for their input. We also thank Alison Evans for her assistance in manuscript preparation. Ian D. Davis is supported by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (APP1102604). We also acknowledge sponsorship from Astellas (platinum sponsor), AstraZeneca, Ipsen, Janssen and Tolmar. Sponsors did not contribute to the APAC APCCC 2018 discussions and were not involved in the development or review of this manuscript.